Yang et al. [21] tested the immunoreactivity of CYP11B1 in a series of 9 ACCs and 190 ACAs with different functional statuses and found the lowest immunoreactivity in ACCs, with an AUC of 0.976, indicating that CYP11B1 has the potential for diagnosing ACC. This evidence concerns the gene CYP11B1 and adrenal cortex carcinoma.